HKSE · 3692.HK
Hansoh Pharmaceutical Group Company Limited
HK$32.54HK$0.00 (0.0%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.41% below the high.
Loading market information…
HKSE · 2096.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Simcere Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Simcere Pharmaceutical Group Limited’s forward annual dividend is HK$0.21 per share, paid annual. The forward yield is 2.01% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Simcere Pharmaceutical Group Limited’s next earnings report is currently expected on Mar 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Simcere Pharmaceutical Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2023 | Aug 21, 2023 | HK$0.93 | HK$3.65B-56.88% vs estimate |
|---|
| Q4 2022 | Mar 31, 2023 | HK$0.39 | HK$4.13B-56.44% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$32.54HK$0.00 (0.0%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.41% below the high.
HK$4.85HK$0.00 (0.0%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.23% below the high.
HK$9.92HK$0.00 (0.0%)
China Medical System Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.05% below the high.
HK$4.38HK$0.00 (0.0%)
Grand Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.84% below the high.
HK$6.84HK$0.00 (0.0%)
The United Laboratories International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
HK$2.60HK$0.00 (0.0%)
SSY Group Limited’s quoted price sits in the upper half of its reported 52-week range, 18.24% below the high.
HK$0.92HK$0.00 (0.0%)
Dawnrays Pharmaceutical (Holdings) Limited’s quoted price sits in the lower half of its reported 52-week range, 26.8% below the high.
